Clinical Trials Browser

Phase 1/2 × Neoplasm, Residual × daratumumab × Clear all

NCT03537599 2025-05-21

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Phase 1/2 Terminated

4 enrolled 7 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual